“The use of bisphosphonates to treat skeletal complications in solid tumours”
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
“The use of bisphosphonates to treat skeletal complications in solid tumours”
Authors
Keywords
Bisphosphonates, Skeletal related events, Hypercalcaemia, Bone metastasis, Breast cancer, Prostate cancer, Lung cancer
Journal
BONE
Volume -, Issue -, Pages 115907
Publisher
Elsevier BV
Online
2021-03-08
DOI
10.1016/j.bone.2021.115907
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†
- (2020) F. Cardoso et al. ANNALS OF ONCOLOGY
- Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton
- (2020) Michael J. Rogers et al. BONE
- Targeting anti-cancer agents to bone using bisphosphonates
- (2020) Lianping Xing et al. BONE
- A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer
- (2020) Mark Clemons et al. EUROPEAN JOURNAL OF CANCER
- Clodronate
- (2020) Eugene McCloskey et al. BONE
- Pharmacology of Bisphosphonates
- (2019) Serge Cremers et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis
- (2019) Arif Ali Awan et al. BREAST CANCER RESEARCH AND TREATMENT
- The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone
- (2019) A. Hussain et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Prostate Cancer and Bone Metastases: The Underlying Mechanisms
- (2019) Sok Kuan Wong et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone metastasis or multiple myeloma: A 12-year longitudinal nationwide healthcare database study
- (2019) Yeon-Hee Baek et al. Cancer Epidemiology
- Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2‐year Clinical Trial
- (2019) Athanasios D. Anastasilakis et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis
- (2018) Seiichi Hosaka et al. International Journal of Clinical Oncology
- Metastatic Spinal Cord Compression: Unraveling the Diagnostic and Therapeutic Challenges
- (2018) STERGIOS BOUSSIOS et al. ANTICANCER RESEARCH
- First‐in‐Human Phase I Study of MBC‐11, a Novel Bone‐Targeted Cytarabine‐Etidronate Conjugate in Patients with Cancer‐Induced Bone Disease
- (2018) Shawn Patrick Zinnen et al. ONCOLOGIST
- Acute Spinal Cord Compression
- (2017) Alexander E. Ropper et al. NEW ENGLAND JOURNAL OF MEDICINE
- Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials
- (2017) F Saad et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Bone Pain and Muscle Weakness in Cancer Patients
- (2017) Daniel P. Milgrom et al. Current Osteoporosis Reports
- Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone
- (2017) Gabriel N. Hortobagyi et al. JAMA Oncology
- Assessing the EORTC QLQ-BM22 Module Using Rasch Modeling and Confirmatory Factor Analysis across Countries: a Comprehensive Psychometric Evaluation in Patients with Bone Metastases
- (2016) Chung-Ying Lin et al. Asian Pacific Journal of Cancer Prevention
- Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer
- (2016) Zachary Klaassen et al. CANCER
- Zoledronic acid increases the antitumor effect of gefitinib treatment for non-small cell lung cancer with EGFR mutations
- (2016) CHENGJUN FENG et al. ONCOLOGY REPORTS
- Novel Pullulan Bioconjugate for Selective Breast Cancer Bone Metastases Treatment
- (2015) Gwénaëlle Bonzi et al. BIOCONJUGATE CHEMISTRY
- Everolimus and Zoledronic Acid in Patients With Renal Cell Carcinoma With Bone Metastases: A Randomized First-Line Phase II Trial
- (2015) Reuben J. Broom et al. Clinical Genitourinary Cancer
- Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
- (2015) LANCET
- Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases
- (2015) Arife Ulas et al. TUMOR BIOLOGY
- Bone health in cancer patients: ESMO Clinical Practice Guidelines
- (2014) R. Coleman et al. ANNALS OF ONCOLOGY
- Treatment sequencing in metastatic castrate-resistant prostate cancer
- (2014) Oliver Sartor et al. ASIAN JOURNAL OF ANDROLOGY
- Denosumab for Treatment of Hypercalcemia of Malignancy
- (2014) Mimi I. Hu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)
- (2014) Matthew R. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update
- (2014) Salvatore L. Ruggiero et al. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
- Real-Time Intravital Imaging Establishes Tumor-Associated Macrophages as the Extraskeletal Target of Bisphosphonate Action in Cancer
- (2014) Simon Junankar et al. Cancer Discovery
- Neutrophil uptake of nitrogen-bisphosphonates leads to the suppression of human peripheral blood γδ T cells
- (2013) Shirin Kalyan et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Comparative Efficacy of Bisphosphonates in Metastatic Breast and Prostate Cancer and Multiple Myeloma: A Mixed-Treatment Meta-analysis
- (2013) C. Palmieri et al. CLINICAL CANCER RESEARCH
- Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial
- (2013) Dino Amadori et al. LANCET ONCOLOGY
- Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial
- (2013) Peter Barrett-Lee et al. LANCET ONCOLOGY
- Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid
- (2012) P.G. Dedes et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Skeletal-related Events and Clinical Outcomes in Patients with Bone Metastases and Normal Levels of Osteolysis: Exploratory Analyses
- (2012) A. Lipton et al. CLINICAL ONCOLOGY
- Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
- (2012) David L. Lacey et al. NATURE REVIEWS DRUG DISCOVERY
- Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
- (2011) F. Saad et al. ANNALS OF ONCOLOGY
- Bisphosphonates in oncology
- (2011) Robert E. Coleman et al. BONE
- Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer
- (2011) Filippo Francini et al. International Journal of Clinical Oncology
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
- (2011) David H. Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- American Society of Clinical Oncology Clinical Practice Guideline Update: Recommendations on the Role of Bone-Modifying Agents in Metastatic Breast Cancer
- (2011) Catherine H. Van Poznak et al. Journal of Oncology Practice
- A promising approach for treatment of tumor-induced bone diseases: Utilizing bisphosphonate derivatives of nucleoside antimetabolites
- (2010) Monica M. Reinholz et al. BONE
- Aminobisphosphonate-pretreated dendritic cells trigger successful Vγ9Vδ2 T cell amplification for immunotherapy in advanced cancer patients
- (2010) Florian Cabillic et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Bone-Targeted Doxorubicin-Loaded Nanoparticles as a Tool for the Treatment of Skeletal Metastases
- (2010) M. Salerno et al. CURRENT CANCER DRUG TARGETS
- Bisphosphonates: Molecular Mechanisms of Action and Effects on Bone Cells, Monocytes and Macrophages
- (2010) A. J. Roelofs et al. CURRENT PHARMACEUTICAL DESIGN
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
- (2010) Alison T. Stopeck et al. JOURNAL OF CLINICAL ONCOLOGY
- Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review
- (2010) Cesar A. Migliorati et al. Nature Reviews Endocrinology
- Zoledronate Stimulates γδ T Cells in Prostate Cancer Patients
- (2010) Michio Naoe et al. ONCOLOGY RESEARCH
- Targeting Bone Metastases with a Bispecific Anticancer and Antiangiogenic Polymer-Alendronate-Taxane Conjugate
- (2009) Keren Miller et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
- (2009) E. Y. Yu et al. CLINICAL CANCER RESEARCH
- Understanding the EORTC QLQ-BM22, the module for patients with bone metastases
- (2009) Edward Chow et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid
- (2008) Allan Lipton et al. CANCER
- Molecular mechanisms and treatment of bone metastasis
- (2008) Gregory A. Clines et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast Activity
- (2008) Vera Hirsh et al. Journal of Thoracic Oncology
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started